The present invention relates to a specialized AI-driven data analytics platform tailored for optimizing engineered
T cell therapies in patients, particularly those undergoing treatment for
cancer, autoimmune diseases, and inflammatory conditions. Unlike general-purpose
AI systems, this platform integrates advanced
machine learning,
deep learning, and
fuzzy logic algorithms to continuously analyze and prioritize real-
time data from multiple sources, including patient monitoring systems, laboratory tests,
imaging modalities, wearable devices, and genomic profiles. The platform is specifically designed to predict and manage adverse events unique to
T cell therapies, such as
Cytokine Release Syndrome (CRS) and Tumor
Lysis Syndrome (TLS), offering clinicians real-time, personalized guidance that dynamically adjusts treatment protocols during and after
T cell infusion. The
system's
adaptive learning capabilities allow it to evolve by incorporating clinical feedback and patient outcomes, continuously refining its predictive models to enhance precision and effectiveness. By providing robust support for managing complex side effects and delivering actionable recommendations, this invention marks a significant advancement in the application of AI to
oncology, offering a highly specialized, innovative approach to enhancing the safety and
efficacy of engineered T
cell therapies.